secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-046068
Event type: other_material
Sentiment:  negative
Materiality: 0.40
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Conduit Pharmaceuticals restates Q1 and Q2 2024 financials; reclassifies deferred commission to current liability
--------------------------------------------------------------------------------

- Previously issued unaudited financials for Q1 and Q2 2024 should no longer be relied upon due to reclassification error.
- Restatement reclassifies deferred commission payable from long-term to current liability; no impact on total liabilities.
- Company will file amendments to its Q1 and Q2 2024 Forms 10-Q to correct the balance sheet classification.
- Discussions with auditor Marcum LLP and Audit Committee led to the non-reliance determination on November 12, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224046068/0001493152-24-046068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224046068/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer